Thank you so much for the information keep suggesting us such informative post i will recommend this post to others ACES ETM
There are separate posts on other drugs which show good results against Covid-19
Also a post that compares GS-441524 research to another similar drug that only had about a 35% coronavirus cure rate GC-376 - GC-376 is owned by another company and also never approved for human or animal use
However GC-376 months ago finished Covid-19 University trials with an application for speedy human trials in Canada and the USA expected to be granted shortly partly based on studies showing a 35% cure rate of coronavirus in cats
Both drugs had been researched and tested by UC Davies over some years with GS-441524 having a near 100% cure rate and being used unofficially extensively to cure pet cats
See links below
A drug labelled GC376 owned by a company called Anivive has already been lab tested in Canada in 2020 in 2 months and promoted for Covid-19 clinical trials and human use partly on the basis it was shown some years ago as effective against a 100% fatal cat coronavirus FIP and tested on cats. It...
Effective Covid-19 treatment could alreay be available. See youtube video interview with Australian Professor Thomas Borody - link at very end - he provides his opinion on why an already effective treatment has been sidelined. Ivermectin (IVM) has been shown very effective in reversing...
Some newly published research awaiting peer review shows Amodiaquine as effective against Covid-19 in hamsters which are often used for testing human treatments or gain of function research. Covid-19 viral material in the lungs was reduced by up to 90% in airborne infection when Amodiaquine was...
Another separate post links to press statements made by Gilead from 2019 saying they wont allow use, development or research of GS-441524 in humans or animals until after Remdesivir has been approved by the FDA.
Two experimental drugs for feline coronavirus could show promise against COVID-19. Could cat drugs treat humans with COVID-19? : Read more
As of early August 2020 nothing had been done and no real updates have been released on how Gilead will cooperate with other researchers on GS-441524
Remdesivir, an antiviral medicine given to hospitalized patients through an IV, was approved by U.S. regulators on Thursday as the first drug to treat COVID-19.
This NIH link on GS-441524 below worked for a short while in October then stopped. Might be a temporary problem. It detailed data about studies of GS-441524
The search originally came up with the data below
NCATS is conducting studies to assess the oral bioavailability of GS-441524 as a potential treatment for SARS-CoV2 infection. Sample Information. Sample Name. GS-441524. NCATS ID. NCGC00686670-1. PubChem SID. 44468216. Molecular Weight. 291.26.
Also unclear if the study below for remdesivir+ is for GS-441524 or remdesivir
ACTIV-5 / Big Effect Trial (BET-B) for the Treatment of COVID-19 - Full Text View.
There are also updates after the date of the the post you replied to which details issues connected to Gilead - a current legal case in the USA where Gilead is accused by 18,000 people in court filings of withholding a better safer drug for 15 years so as to have a replacement drug in the future.
The legal case claim is Gilead withheld the better drug patent so as not to compete with a much more toxic drug. Both drugs were developed at the same time. Gilead all the time had the test data showing which drug was safer and how the more toxic released drug caused harm and even death. Once the more toxic drug patent expired 15 years later - Gilead then released the safer drug as a new safer version of the previous treatment. Gilead is accused of putting profit over safety and health.
In May 2020 Cancer researchers from the University of Texas set out in some detail why Gileads drug GS-441524 was superior to Gileads Remdesivir as a Coronavirus treatment. This was based both on animals trials and previous research on GS-441524. In some animals trials GS-441524 was compared...